Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06422520 · ClinicalTrials.gov registry record · Phase 1

A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by BeiGene.

Active
Registry status
Phase 1
Development phase
120
Enrollment target
14
Study locations

NCT06422520 is a Phase 1 study of Advanced Solid Tumor that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 120 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (37% lower). The trial reports 14 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06422520, a Phase 1 study of Advanced Solid Tumor, is active but no longer recruiting, sponsored by BeiGene.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
120 participants
Enrollment target
14
Study locations

Study Summary

This is a first-in-human, Phase 1a/1b study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BGB-C354 alone and in combination with tislelizumab in participants with advanced solid tumors. Study details include: * The study will be conducted in 2 phases: Phase 1a (Monotherapy Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion). * The visit frequency will be approximately every 21 days during study treatment. Maximum treatment duration will be up to two years. * The study duration is estimated to be approximately 5 years.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG Tislelizumab
  • DRUG BGB-C354

Study Locations (14)

Texas

  • The University of Texas Md Anderson Cancer Center - Houston
  • Next Oncology - San Antonio

Victoria

  • St Vincents Hospital Melbourne - Fitzroy
  • The Alfred Hospital - Melbourne

Florida

  • Florida Cancer Specialist Research Institute Lake Nona - Orlando

Massachusetts

  • Dana Farber Cancer Institute - Boston

Missouri

  • Washington University School of Medicine - St Louis

New South Wales

  • Westmead Hospital - Westmead

Western Australia

  • One Clinical Research - Nedlands

Beijing Municipality

  • Beijing Cancer Hospital - Beijing

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-07-08
Est. Completion 2027-01-31
Phase Phase 1

Sponsor

BeiGene

65 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06422520

The ClinicalTrials.gov registry entry for NCT06422520 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (37% lower). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Tislelizumab is the first listed.

NCT06422520 reports 14 study locations spanning 12 distinct geographic areas - top geographies include Texas, Victoria, Florida.

Frequently Asked Questions

What is clinical trial NCT06422520 about?

NCT06422520 is a clinical study titled "A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors". This is a first-in-human, Phase 1a/1b study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BGB-C354 alone and in combination with tislelizumab in participants with advanced solid tumors. Study details include: * The study will be conducted in 2 phases...

What is the current status of trial NCT06422520?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2024-07-08. Estimated completion is 2027-01-31.

What conditions does trial NCT06422520 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06422520?

The interventions under investigation include: Tislelizumab (DRUG), BGB-C354 (DRUG).

Who is sponsoring clinical trial NCT06422520?

This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06422520 being conducted?

This trial has 14 study locations across Florida, Massachusetts, Missouri, Texas, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.